Suppr超能文献

晚期肾病糖尿病患者尿中吡咯赖氨酸和戊糖苷浓度的解离。

Dissociation between urinary pyrraline and pentosidine concentrations in diabetic patients with advanced nephropathy.

作者信息

Aso Yoshimasa, Takanashi Keishi, Sekine Kyouichi, Yoshida Noboru, Takebayashi Kohzo, Yoshihara Kazuhiro, Inukai Toshihiko

机构信息

The Department of Internal Medicine, Koshigaya Hospital, Dokkyo University School of Medicine, Saitama, Japan.

出版信息

J Lab Clin Med. 2004 Aug;144(2):92-9. doi: 10.1016/j.lab.2004.03.016.

Abstract

It has been reported that the concentrations of both pyrraline and pentosidine, well-characterized advanced glycation end products, are increased in the urine of diabetic patients. To determine factors that influence the urinary excretion of pyrraline or pentosidine, we compared pyrraline or pentosidine concentrations with glycemic-control indexes, urinary albumin excretion, and urinary beta2-microglobulin in patients with type 2 diabetes. The study was conducted in 39 age-matched healthy control subjects and 50 diabetic patients, including 22 patients with normoalbuminuria, 15 with microalbuminuria, and 13 with macroalbuminuria. Both urinary pyrraline and pentosidine were measured in early-morning urine specimens with the use of high-pressure liquid chromatography. The urinary pentosidine concentration was significantly higher in diabetic patients than in control subjects (P <.01). In contrast, the urinary pyrraline concentration was significantly lower in diabetic patients than in control subjects (P <.001). Urinary pentosidine concentrations were greater in diabetic patients with macroalbuminuria and microalbuminuria than in those with normoalbuminuria. However, urinary pyrraline concentrations were significantly lower in diabetic patients with advanced nephropathy. Both the hemoglobin A(1c) (HbA(1c)) and the preceding year's mean HbA(1c) were lower in patients with macroalbuminuria than in those with normoalbuminuria or microalbuminuria. Urinary pyrraline, but not pentosidine, showed a significantly positive correlation with the preceding year's mean HbA(1c) (P<0.01). Multivariate analysis disclosed that urinary beta-2-microglobulin was independently correlated with the urinary concentrations of pentosidine and pyrraline (P <.05 for both). We conclude that the urinary concentration of pentosidine is greater in diabetic patients with overt nephropathy, whereas the urinary pyrraline concentration is significantly lower in diabetic patients with overt nephropathy. Because urinary pyrraline is more directly influenced by glycemia than by pentosidine, the difference in glycemic control among diabetic patients with various grades of nephropathy may be responsible for a dissociation between urinary pyrraline and pentosidine concentrations in patients with overt diabetic nephropathy.

摘要

据报道,糖尿病患者尿液中吡咯赖氨酸和戊糖苷(均为特征明确的晚期糖基化终产物)的浓度会升高。为了确定影响吡咯赖氨酸或戊糖苷尿排泄的因素,我们比较了2型糖尿病患者的吡咯赖氨酸或戊糖苷浓度与血糖控制指标、尿白蛋白排泄量及尿β2-微球蛋白。该研究纳入了39名年龄匹配的健康对照者和50名糖尿病患者,其中包括22名正常白蛋白尿患者、15名微量白蛋白尿患者和13名大量白蛋白尿患者。使用高压液相色谱法测定清晨尿液标本中的尿吡咯赖氨酸和戊糖苷。糖尿病患者的尿戊糖苷浓度显著高于对照者(P<.01)。相反,糖尿病患者的尿吡咯赖氨酸浓度显著低于对照者(P<.001)。大量白蛋白尿和微量白蛋白尿的糖尿病患者的尿戊糖苷浓度高于正常白蛋白尿患者。然而,晚期肾病的糖尿病患者尿吡咯赖氨酸浓度显著降低。大量白蛋白尿患者的糖化血红蛋白A1c(HbA1c)及前一年的平均HbA1c均低于正常白蛋白尿或微量白蛋白尿患者。尿吡咯赖氨酸而非戊糖苷与前一年的平均HbA1c呈显著正相关(P<0.01)。多变量分析显示,尿β2-微球蛋白与尿戊糖苷和吡咯赖氨酸浓度独立相关(两者P<.05)。我们得出结论,显性肾病的糖尿病患者尿戊糖苷浓度更高,而显性肾病的糖尿病患者尿吡咯赖氨酸浓度显著更低。由于尿吡咯赖氨酸比戊糖苷更直接受血糖影响,不同程度肾病的糖尿病患者血糖控制的差异可能是显性糖尿病肾病患者尿吡咯赖氨酸和戊糖苷浓度分离的原因。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验